Heart-Saving combo tested in leukemia patients

NCT ID NCT04977180

Recruiting now Disease control Sponsor: University of Virginia Source: ClinicalTrials.gov ↗

First seen May 08, 2026 · Last updated May 20, 2026 · Updated 3 times

Summary

This study tests whether giving two common heart medications (a beta blocker and an ACE inhibitor) during intensive chemotherapy can prevent heart damage in people newly diagnosed with acute myeloid leukemia (AML). About 70 adults will be randomly assigned to receive the heart drugs or not. The main goal is to see how many develop heart problems, and researchers will also track quality of life and other heart function changes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of Virginia
RECRUITING

Charlottesville, Virginia, 22903, United States

Contact Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

ACUTE MYELOID LEUKEMIA AML